IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the life sciences industry. IntegraGen was selected by a committee of healthcare industry experts, due to the partnership established in North America with GoPath Laboratories. Earlier this year, IntegraGen Laboratories and GoPath signed a licensing agreement enabling GoPath to offer a laboratory-developed test (miR-31now ™). Several clinical studies have confirmed that the miR-31-3p expression test predicts response to anti-EGFR therapy in patients with metastatic colorectal cancer.